WOS期刊SCI分区是指SCI官方(Web of
Science)为每个学科内的期刊按照IF数值排序,将期刊按照四等分的方法划分的Q1-Q4等级,Q1代表质量最高,即常说的1区期刊。
(2022-2023年最新版)
ONCOLOGY
Q1
测一测你投这本期刊的成功率
【官方推荐】国内首个期刊投稿预测系统,多维度分析投稿成功率,助你精准决策
12274
人已预测
期刊介绍
Annals of Oncology, the journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology, provides rapid and efficient peer-review publications on innovative cancer treatments or translational work related to oncology and precision medicine.Main focuses of interest include: systemic anticancer therapy (with specific interest on molecular targeted agents and new immune therapies), randomized trials (including negatives ones), top-level guidelines, and new fields currently emerging as key components of personalized medicine, such as molecular pathology, bioinformatics, modern statistics, and biotechnologies. Radiotherapy, surgery and pediatrics manuscripts can be considered if they display a clear interaction with one of the fields above or are paradigm-shifting.
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
来源期刊:Annals of oncology : official journal of the European Society for Medical Oncology
DOI:10.1093/annonc/mdz012
Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration
来源期刊:Annals of Oncology
DOI:10.1093/annonc/mdz394.019
Molecular pathology of tumors of the central nervous system
来源期刊:Annals of Oncology
DOI:10.1093/annonc/mdz164
Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)
来源期刊:Annals of Oncology
DOI:10.1093/annonc/mdz253.016
Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
来源期刊:Annals of Oncology
DOI:10.1093/annonc/mdz260.010
已经到底了~
测一测你投这本期刊的成功率
【官方推荐】国内首个期刊投稿预测系统,多维度分析投稿成功率,助你精准决策
12274
人已预测
鹿粉191597
2022-11-08 12:28:09
投出去以后,with editor 2天,under review 15天,with editor 2天,最后是reject without peer review